Tag - STSA

Satsuma Pharmaceuticals

SVB Leerink starts Satsuma Pharma at OP; PT $20

SVB Leerink launched coverage of Satsuma Pharmaceuticals (NASDAQ:STSA) with an “outperform” rating and $20 price target. The stock closed at $10.70 on Oct. 7. STS101, Satsuma’s lead asset, is a dry-powder formulation of...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.